瑞士健康保险对大量减肥后症状性腹部组织过剩手术治疗的报销政策:一项回顾性队列研究。

IF 2.9 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Valeria Pruzzo, Francesca Bonomi, Leon Guggenheim, Astrid Navarra, Daniel Schmauss, Reto Wettstein, Yves Harder
{"title":"瑞士健康保险对大量减肥后症状性腹部组织过剩手术治疗的报销政策:一项回顾性队列研究。","authors":"Valeria Pruzzo, Francesca Bonomi, Leon Guggenheim, Astrid Navarra, Daniel Schmauss, Reto Wettstein, Yves Harder","doi":"10.3390/jcm14186617","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Patients with symptomatic abdominal tissue excess following massive weight loss (MWL) often experience skin affections associated with hygiene challenges, functional impairments, and psychological distress, all of which significantly impact their quality of life (QoL). Abdominoplasty effectively addresses these issues when conservative treatments prove ineffective. However, health insurance companies (HICs) in Switzerland frequently deny reimbursement. This study aimed to evaluate HIC's reimbursement policies for abdominoplasty, quantifying time delays and additional costs generated by reconsideration due to initial rejections while assessing postoperative QoL of patients. <b>Methods</b>: A retrospective cohort study was conducted including patients undergoing abdominoplasty for symptomatic abdominal tissue excess after MWL between July 2019 and December 2023. Eligibility required HIC approval, informed consent, and legal age. Primary outcomes measured the number of reimbursement requests needed per patient, duration until approval, and additional diagnostic and therapeutic interventions following rejection. Secondary outcomes focused on additional consequent costs, differences in baseline characteristics and symptomatology, as well as QoL improvements using a non-validated, study-specific questionnaire. <b>Results</b>: Of 52 patients included, 33 received cost approval after a single request, whereas 19 required multiple submissions. The mean duration until approval was 15 weeks, with a 26-week delay for the multiple-request group, generating additional costs of CHF 715 per patient. Moreover, abdominoplasty significantly improved QoL in all patients, with no differences between groups. <b>Conclusions</b>: Initial reimbursement denials caused treatment delays, prolonged symptomatology, and increased healthcare costs, despite clear surgical indications. However, future studies involving larger cohorts are needed to support these findings.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"14 18","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470673/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reimbursement Policies of Swiss Health Insurances for the Surgical Treatment of Symptomatic Abdominal Tissue Excess After Massive Weight Loss: A Retrospective Cohort Study.\",\"authors\":\"Valeria Pruzzo, Francesca Bonomi, Leon Guggenheim, Astrid Navarra, Daniel Schmauss, Reto Wettstein, Yves Harder\",\"doi\":\"10.3390/jcm14186617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background</b>: Patients with symptomatic abdominal tissue excess following massive weight loss (MWL) often experience skin affections associated with hygiene challenges, functional impairments, and psychological distress, all of which significantly impact their quality of life (QoL). Abdominoplasty effectively addresses these issues when conservative treatments prove ineffective. However, health insurance companies (HICs) in Switzerland frequently deny reimbursement. This study aimed to evaluate HIC's reimbursement policies for abdominoplasty, quantifying time delays and additional costs generated by reconsideration due to initial rejections while assessing postoperative QoL of patients. <b>Methods</b>: A retrospective cohort study was conducted including patients undergoing abdominoplasty for symptomatic abdominal tissue excess after MWL between July 2019 and December 2023. Eligibility required HIC approval, informed consent, and legal age. Primary outcomes measured the number of reimbursement requests needed per patient, duration until approval, and additional diagnostic and therapeutic interventions following rejection. Secondary outcomes focused on additional consequent costs, differences in baseline characteristics and symptomatology, as well as QoL improvements using a non-validated, study-specific questionnaire. <b>Results</b>: Of 52 patients included, 33 received cost approval after a single request, whereas 19 required multiple submissions. The mean duration until approval was 15 weeks, with a 26-week delay for the multiple-request group, generating additional costs of CHF 715 per patient. Moreover, abdominoplasty significantly improved QoL in all patients, with no differences between groups. <b>Conclusions</b>: Initial reimbursement denials caused treatment delays, prolonged symptomatology, and increased healthcare costs, despite clear surgical indications. However, future studies involving larger cohorts are needed to support these findings.</p>\",\"PeriodicalId\":15533,\"journal\":{\"name\":\"Journal of Clinical Medicine\",\"volume\":\"14 18\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470673/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcm14186617\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm14186617","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:大量体重减轻(MWL)后出现症状性腹部组织过剩的患者通常会经历与卫生挑战、功能障碍和心理困扰相关的皮肤病变,所有这些都会显著影响他们的生活质量(QoL)。当保守治疗无效时,腹部成形术有效地解决了这些问题。然而,瑞士的医疗保险公司经常拒绝报销。本研究旨在评估HIC对腹部成形术的报销政策,量化由于初始排斥而重新考虑所产生的时间延迟和额外费用,同时评估患者的术后生活质量。方法:回顾性队列研究包括2019年7月至2023年12月期间因MWL后症状性腹部组织过剩而接受腹部成形术的患者。资格要求HIC批准,知情同意和法定年龄。主要结果测量了每位患者所需的报销请求数量、批准前的持续时间以及拒绝后的额外诊断和治疗干预。次要结果集中在额外的后续费用,基线特征和症状学的差异,以及使用未经验证的研究特定问卷的生活质量改善。结果:纳入的52例患者中,33例在单次申请后获得费用批准,19例需要多次申请。到批准的平均时间为15周,多请求组延迟26周,每位患者产生715瑞士法郎的额外费用。此外,腹部成形术显著改善了所有患者的生活质量,组间无差异。结论:尽管有明确的手术指征,但最初的报销拒绝导致治疗延误、症状延长和医疗费用增加。然而,未来需要更大规模的研究来支持这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Reimbursement Policies of Swiss Health Insurances for the Surgical Treatment of Symptomatic Abdominal Tissue Excess After Massive Weight Loss: A Retrospective Cohort Study.

Reimbursement Policies of Swiss Health Insurances for the Surgical Treatment of Symptomatic Abdominal Tissue Excess After Massive Weight Loss: A Retrospective Cohort Study.

Reimbursement Policies of Swiss Health Insurances for the Surgical Treatment of Symptomatic Abdominal Tissue Excess After Massive Weight Loss: A Retrospective Cohort Study.

Reimbursement Policies of Swiss Health Insurances for the Surgical Treatment of Symptomatic Abdominal Tissue Excess After Massive Weight Loss: A Retrospective Cohort Study.

Background: Patients with symptomatic abdominal tissue excess following massive weight loss (MWL) often experience skin affections associated with hygiene challenges, functional impairments, and psychological distress, all of which significantly impact their quality of life (QoL). Abdominoplasty effectively addresses these issues when conservative treatments prove ineffective. However, health insurance companies (HICs) in Switzerland frequently deny reimbursement. This study aimed to evaluate HIC's reimbursement policies for abdominoplasty, quantifying time delays and additional costs generated by reconsideration due to initial rejections while assessing postoperative QoL of patients. Methods: A retrospective cohort study was conducted including patients undergoing abdominoplasty for symptomatic abdominal tissue excess after MWL between July 2019 and December 2023. Eligibility required HIC approval, informed consent, and legal age. Primary outcomes measured the number of reimbursement requests needed per patient, duration until approval, and additional diagnostic and therapeutic interventions following rejection. Secondary outcomes focused on additional consequent costs, differences in baseline characteristics and symptomatology, as well as QoL improvements using a non-validated, study-specific questionnaire. Results: Of 52 patients included, 33 received cost approval after a single request, whereas 19 required multiple submissions. The mean duration until approval was 15 weeks, with a 26-week delay for the multiple-request group, generating additional costs of CHF 715 per patient. Moreover, abdominoplasty significantly improved QoL in all patients, with no differences between groups. Conclusions: Initial reimbursement denials caused treatment delays, prolonged symptomatology, and increased healthcare costs, despite clear surgical indications. However, future studies involving larger cohorts are needed to support these findings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Clinical Medicine
Journal of Clinical Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
5.70
自引率
7.70%
发文量
6468
审稿时长
16.32 days
期刊介绍: Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals. Unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes. There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信